Study on Pemetrexed and Carboplatin with Radiotherapy for Lung Cancer
Author Information
Author(s): Shen Xinglei, DeNittis Albert, Wernwer-Wasik Maria, Axelrod Rita, Gilman Paul, Meyer Thomas, Treat Joseph, Curran Walter J, Machtay Mitchell
Primary Institution: Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University
Hypothesis
Is dose-dense pemetrexed combined with carboplatin and radiotherapy feasible for treating locally advanced non-small cell lung cancer?
Conclusion
The combination of carboplatin with dose-dense pemetrexed and involved field radiotherapy is feasible and shows promising results in patients with locally advanced and oligometastatic NSCLC.
Supporting Evidence
- Thirteen of 16 patients had in-field local regional response.
- The median follow-up time was 17.8 months.
- The actuarial median survival time was 28.6 months in all patients.
- Two patients experienced dose-limiting toxicities.
- Neutropenia was the most common toxicity observed.
Takeaway
Doctors tested a new way to treat lung cancer using a special medicine and radiation together, and it worked pretty well for many patients.
Methodology
Patients received carboplatin and dose-dense pemetrexed during radiotherapy, with dose adjustments based on toxicity.
Potential Biases
Potential bias due to the study being investigator-initiated and supported by a pharmaceutical company.
Limitations
The study had a small sample size and was not powered for efficacy assessment.
Participant Demographics
Median age was 70, with most patients having stage III disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website